# Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

> **NCT02925416** · PHASE4 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 22 (actual)

## Conditions studied

- Skin Diseases, Bacterial

## Interventions

- **DRUG:** Oritavancin
- **DRUG:** Placebo (D5W)

## Key facts

- **NCT ID:** NCT02925416
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-24
- **Primary completion:** 2017-06-20
- **Final completion:** 2017-06-20
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02925416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02925416, "Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02925416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*